$AMRN re China reposting this from Terrapharma1 Eddingpharm ( $AMRN 's China partner) updated their website. Google Translate: Vascepa is expected to be listed in Hong Kong, China, Taiwan and Mainland China starting from 2022. Note that while current China study is for >500TG, if the study is successful and if the ethnic studies (that Eddingpharm says they have already completed) are fine, they are allowed to submit REDUCE-IT results for approval. China's approval process is super fast compared to FDA. twitter.com/TerraPharma1/st...
  • 15
15 Likes